Bamlanivimab: Continued monitoring

As for all medicines, Health Canada will continue to monitor the safety of bamlanivimab in Canada closely. We will take prompt action should any safety concerns arise.

Health Canada will provide updates on post-market activities related to bamlanivimab in the Post-Authorization Activity Table (PAAT) found in the vaccines and treatments regulatory portal.

Related links

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: